Wei-ChuVictoriaLaiMD

PubMed

• 3 citations
  Rationale and Design of the Phase 3 KEYLYNK-013 Study of Pembrolizumab With Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Limited...
  Andreas Rimner, Wei-Chu Victoria Lai, Raffaele Califano, Salma K Jabbour, Charles M Rudin, Corinne Faivre-Finn, Byoung Chul Cho, Terufumi Kato, Jinming Yu, Wyatt Chafi...> ;Clinical Lung Cancer. 2022 Jul 1
• Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study.
  Lai, W. V.,Lebas, L.,Barnes, T. A.,Milia, J.,Ni, A.,Gautschi, O.,Peters, S.,Ferrara, R.,Plodkowski, A. J.,Kavanagh, J.,Sabari, J. K.,Clarke, S. J.,Pavlakis, N.,Drilon,...> ;Eur. J. Cancer. 2019 Jan 28
• 204 citations
  PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers.
  Joshua K. Sabari, Giulia Costanza Leonardi, Catherine A. Shu, Renato Umeton, Joseph Montecalvo, Ai Ni, Ruqin Chen, Jules L. Dienstag, Chebli Mrad, Isabella Bergagnini,...> ;Annals of Oncology. 2018 Oct 1

Lectures

• Real-world experience and molecular features of response to immune checkpoint blockade in patients with recurrent small cell lung cancer. 
  2019 ASCO Annual Meeting - 6/1/2019
• PD-L1 expression, tumor mutation burden and response to immune checkpoint blockade in patients with HER2-mutant lung cancers. 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018